Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1]
It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.[2]
- Market Cap ₹ 1,08,316 Cr.
- Current Price ₹ 3,201
- High / Low ₹ 3,591 / 2,407
- Stock P/E 62.3
- Book Value ₹ 222
- Dividend Yield 0.87 %
- ROCE 23.2 %
- ROE 24.2 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company has been maintaining a healthy dividend payout of 73.8%
- Company's working capital requirements have reduced from 72.1 days to 53.1 days
Cons
- Stock is trading at 14.7 times its book value
- The company has delivered a poor sales growth of 6.93% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE Quality Index Nifty Pharma Nifty 100 Low Volatility 30 Nifty LargeMidcap 250 Nifty 500
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3,203 | 4,172 | 4,636 | 6,687 | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,225 | |
2,506 | 3,216 | 3,616 | 3,954 | 4,438 | 4,601 | 5,690 | 5,769 | 5,524 | 6,077 | 6,778 | 7,360 | 7,630 | |
Operating Profit | 697 | 955 | 1,020 | 2,733 | 1,377 | 1,349 | 1,983 | 2,170 | 2,480 | 2,431 | 2,842 | 3,368 | 3,595 |
OPM % | 22% | 23% | 22% | 41% | 24% | 23% | 26% | 27% | 31% | 29% | 30% | 31% | 32% |
1 | 34 | 286 | 32 | 223 | 299 | -300 | 121 | 57 | -288 | 45 | 146 | 94 | |
Interest | 34 | 59 | 175 | 184 | 206 | 308 | 504 | 451 | 353 | 255 | 333 | 354 | 299 |
Depreciation | 83 | 87 | 191 | 238 | 307 | 409 | 618 | 654 | 658 | 662 | 707 | 808 | 811 |
Profit before tax | 582 | 844 | 940 | 2,343 | 1,088 | 931 | 562 | 1,187 | 1,526 | 1,226 | 1,847 | 2,352 | 2,579 |
Tax % | 25% | 21% | 20% | 26% | 14% | 27% | 22% | 14% | 18% | 37% | 33% | 30% | |
435 | 664 | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,802 | |
EPS in Rs | 12.79 | 19.62 | 22.19 | 51.22 | 27.59 | 20.04 | 12.89 | 30.28 | 36.99 | 22.97 | 36.79 | 48.94 | 53.25 |
Dividend Payout % | 45% | 25% | 25% | 34% | 25% | 35% | 66% | 53% | 47% | 105% | 60% | 57% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 7% |
3 Years: | 10% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 22% |
3 Years: | 8% |
TTM: | 30% |
Stock Price CAGR | |
---|---|
10 Years: | 19% |
5 Years: | 27% |
3 Years: | 27% |
1 Year: | 33% |
Return on Equity | |
---|---|
10 Years: | 23% |
5 Years: | 21% |
3 Years: | 21% |
Last Year: | 24% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 42 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 |
Reserves | 1,380 | 1,818 | 2,406 | 3,409 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 | 7,335 |
693 | 1,132 | 2,740 | 2,352 | 2,510 | 6,462 | 6,038 | 5,784 | 4,874 | 4,070 | 5,369 | 4,022 | 3,128 | |
1,638 | 1,988 | 2,589 | 3,040 | 2,740 | 3,159 | 3,351 | 3,402 | 3,363 | 2,884 | 3,043 | 3,627 | 4,456 | |
Total Liabilities | 3,753 | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 15,088 |
820 | 875 | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,121 | 8,138 | 7,890 | |
CWIP | 285 | 534 | 678 | 1,042 | 519 | 647 | 617 | 712 | 889 | 630 | 765 | 361 | 412 |
Investments | 60 | 186 | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 | 127 |
2,587 | 3,427 | 4,011 | 4,206 | 4,589 | 5,249 | 5,395 | 5,763 | 5,940 | 5,628 | 5,524 | 5,834 | 6,659 | |
Total Assets | 3,753 | 5,022 | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 15,088 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
153 | 599 | 810 | 2,742 | 1,009 | 894 | 1,798 | 1,393 | 2,005 | 1,803 | 2,368 | 3,266 | |
-247 | -418 | -2,113 | -869 | -798 | -4,677 | -246 | 229 | -444 | -196 | -2,335 | -160 | |
20 | 86 | 1,212 | -1,435 | -193 | 3,417 | -1,314 | -1,549 | -1,651 | -1,781 | 77 | -2,780 | |
Net Cash Flow | -73 | 268 | -90 | 437 | 18 | -366 | 238 | 73 | -89 | -174 | 110 | 327 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 78 | 96 | 125 | 79 | 60 | 77 | 68 | 76 | 69 | 70 | 74 | 63 |
Inventory Days | 364 | 297 | 275 | 314 | 318 | 429 | 318 | 362 | 456 | 368 | 298 | 310 |
Days Payable | 421 | 421 | 472 | 523 | 356 | 447 | 345 | 345 | 351 | 250 | 224 | 284 |
Cash Conversion Cycle | 22 | -28 | -71 | -130 | 21 | 59 | 42 | 93 | 174 | 188 | 147 | 89 |
Working Capital Days | 33 | 42 | 54 | -1 | 28 | 20 | -17 | -2 | 82 | 89 | 74 | 53 |
ROCE % | 33% | 35% | 27% | 48% | 19% | 13% | 13% | 15% | 17% | 19% | 20% | 23% |
Documents
Announcements
-
Corporate Action-Board to consider Dividend
1d - Record date set for interim dividend payment.
-
Board Meeting Intimation for To Consider And Approve The Audited Financial Results On Standalone Basis And Unaudited Financial Results And Interim Dividend
1d - Board meeting on 24-Jan-25 to approve financial results.
- Closure of Trading Window 27 Dec
-
Announcement under Regulation 30 (LODR)-Issue of Securities
26 Dec - Company issued Commercial Papers worth ₹200 Crores.
-
Redemption Of Commercial Papers
19 Dec - Full redemption of ₹200 crores Commercial Papers on maturity.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Oct 2024TranscriptPPTREC
-
Jul 2024TranscriptPPT
-
May 2024TranscriptPPT
-
Feb 2024TranscriptPPT
-
Aug 2023TranscriptPPT
-
May 2023TranscriptPPT
-
Sep 2022TranscriptNotesPPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Jul 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Oct 2018TranscriptPPT
-
Jul 2018TranscriptPPT
-
May 2018TranscriptNotesPPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Oct 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
May 2016TranscriptPPT
Product Segments Q2 FY25
1) Branded Generics (74%): [1] The company’s branded generics business focuses on the manufacturing pharmaceutical products under its brand names catering to various therapeutic segments including cardiovascular, central nervous system, gastrointestinal, vitamin mineral nutrients, dermatology, diabetes, pain management and gynecology. Its branded generic medicines are marketed in key regions including India and Brazil. [2]